Sera Prognostics (NASDAQ:SERA) Stock Rating Upgraded by Zacks Investment Research

Sera Prognostics (NASDAQ:SERAGet Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Wednesday, Zacks.com reports.

According to Zacks, “Sera Prognostics Inc. is a women’s health diagnostics company. It focused on improving maternal and neonatal health by providing pregnancy biomarker information to doctors and patients. Sera Prognostics Inc. is based in SALT LAKE CITY. “

Several other equities research analysts also recently weighed in on the stock. Berenberg Bank started coverage on shares of Sera Prognostics in a research note on Wednesday, April 27th. They set a “buy” rating on the stock. Citigroup downgraded shares of Sera Prognostics from a “buy” rating to a “neutral” rating in a research report on Wednesday, March 30th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $18.50.

Shares of SERA opened at $2.15 on Wednesday. Sera Prognostics has a fifty-two week low of $1.98 and a fifty-two week high of $15.50. The business’s 50 day simple moving average is $3.37.

Sera Prognostics (NASDAQ:SERAGet Rating) last announced its earnings results on Tuesday, March 29th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.12). As a group, analysts predict that Sera Prognostics will post -1.46 earnings per share for the current year.

Several large investors have recently made changes to their positions in the business. Sanders Morris Harris LLC increased its position in shares of Sera Prognostics by 9.8% in the 1st quarter. Sanders Morris Harris LLC now owns 630,737 shares of the company’s stock valued at $2,391,000 after purchasing an additional 56,457 shares during the last quarter. Norges Bank purchased a new stake in shares of Sera Prognostics in the 4th quarter valued at approximately $255,000. BlackRock Inc. grew its position in shares of Sera Prognostics by 18.3% in the 4th quarter. BlackRock Inc. now owns 177,422 shares of the company’s stock valued at $1,220,000 after buying an additional 27,436 shares during the last quarter. Skye Global Management LP grew its position in shares of Sera Prognostics by 5.6% in the 4th quarter. Skye Global Management LP now owns 376,000 shares of the company’s stock valued at $2,583,000 after buying an additional 20,000 shares during the last quarter. Finally, State Street Corp grew its position in shares of Sera Prognostics by 33.3% in the 4th quarter. State Street Corp now owns 40,801 shares of the company’s stock valued at $280,000 after buying an additional 10,201 shares during the last quarter. 63.20% of the stock is currently owned by institutional investors.

About Sera Prognostics (Get Rating)

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies.

Further Reading

Get a free copy of the Zacks research report on Sera Prognostics (SERA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Sera Prognostics (NASDAQ:SERA)

Receive News & Ratings for Sera Prognostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sera Prognostics and related companies with MarketBeat.com's FREE daily email newsletter.